Dayvigo Cost in Mississippi 2026: Prices, Medicaid, and Cheaper Alternatives

What Does Dayvigo Actually Cost in Mississippi?

Dayvigo's Eisai wholesale acquisition price sits near $320 per month for either the 5 mg or 10 mg tablet, but almost no cash-pay patient in Mississippi pays that figure. Retail pharmacy survey data for 2026 show an average cash price of roughly $85 per month across Mississippi chains and independent pharmacies, depending on location and which coupon platform you use.

The gap between list price and cash price exists because pharmacy benefit managers negotiate rebates that never reach uninsured patients directly. Applying a GoodRx or NeedyMeds coupon at checkout captures a slice of that negotiated price. A 30-tablet supply of lemborexant 10 mg is priced between $78 and $95 at most Jackson, Gulfport, and Hattiesburg pharmacies when a coupon code is presented. Without any coupon, the same supply can ring up at $290 to $310.

Dayvigo is a Schedule IV controlled substance under the Controlled Substances Act, the same schedule as zolpidem (FDA). That scheduling matters for Mississippi patients because state law requires a separate prescription for each 30-day fill; no automatic refills are permitted.

The FDA approved lemborexant in December 2019 based on the SUNRISE-1 and SUNRISE-2 trials. SUNRISE-1 (N=291, JAMA Network Open 2019) showed lemborexant 10 mg reduced subjective sleep onset latency by 17.4 minutes versus placebo at month one, with benefit sustained through the six-month endpoint (SUNRISE-1). That efficacy profile, combined with a favorable next-morning driving safety result versus zolpidem extended-release, positioned Dayvigo as a clinically differentiated option (FDA label).

Does Mississippi Medicaid Cover Dayvigo?

Mississippi Medicaid does not cover Dayvigo as of 2026. The Mississippi Division of Medicaid (DOM) preferred drug list excludes lemborexant from covered sleep agents; suvorexant (Belsomra), eszopiclone (Lunesta generics), and zolpidem generics remain the preferred options on that formulary (Mississippi DOM PDL).

Patients enrolled in Mississippi Medicaid who need an orexin receptor antagonist may request a prior authorization exception, but DOM policy historically denies these when a preferred alternative exists in the same pharmacological class. Suvorexant, the only other FDA-approved dual orexin receptor antagonist, has a generic expected in the mid-2020s that may lower the cost barrier for Medicaid patients who specifically need a DORA mechanism (PubMed: DORA pharmacology review).

The American Academy of Sleep Medicine 2017 clinical practice guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults", a recommendation made before lemborexant received approval (AASM guideline). Mississippi Medicaid's formulary reflects that older guidance. Clinicians filing a prior authorization for lemborexant should document why suvorexant is not clinically appropriate for the specific patient.

Mississippi dual-eligible beneficiaries (Medicare-Medicaid) should check Part D formulary tiers, as some Part D plans do cover Dayvigo at tier 3 or tier 4 with a copay between $47 and $110 per month depending on the plan year. The Medicare coverage gap affects cost at higher fill volumes (CMS Part D formulary search).

Which Private Insurance Plans Cover Dayvigo in Mississippi?

Coverage varies sharply by plan. BlueCross BlueShield of Mississippi, Humana, and United Healthcare commercial plans in Mississippi generally place lemborexant on tier 3 (non-preferred brand) of their 2026 formularies, producing a copay of $60 to $130 per 30-day fill after deductible. Aetna CVS Health plans in Mississippi list lemborexant at tier 4 in some group benefit designs, which can push the copay to $150 or more.

Prior authorization is standard across all Mississippi commercial plans that cover Dayvigo. The typical requirements include: documentation of insomnia duration of at least three months, a trial of at least one preferred sleep agent (usually zolpidem or eszopiclone generic), and a prescriber attestation that the patient experienced inadequate response or tolerability issues with that agent (FDA: insomnia drug approval background).

Step therapy, being required to try and fail a cheaper drug first, delays access by an average of 30 to 90 days. Physicians filing appeals should reference the SUNRISE-2 trial data showing statistically significant improvement in subjective total sleep time (mean increase of 28.1 minutes for lemborexant 10 mg versus 12.9 minutes for placebo, P<0.001) to support medical necessity (SUNRISE-2 full text).

How the Eisai Savings Card Works in Mississippi

Eisai offers a co-pay savings card for commercially insured patients that can reduce the monthly cost to as low as $30 for eligible Mississippi residents. The program is not valid for patients using Medicare Part D, Medicaid, or any other government-funded program. Mississippi patients who qualify can enroll at the Eisai patient support portal and present the card at any participating retail pharmacy.

The savings card covers up to a set annual benefit cap, typically $2,500 to $3,600 per calendar year depending on program terms at the time of enrollment. Once that cap is reached, patients revert to their plan's standard cost-sharing for the remainder of the year. Read the current terms at enrollment because Eisai adjusts the cap annually (FDA drug information page).

Patients without any insurance who present the Eisai savings card may receive a different discount structure. Cash-pay patients should compare the post-card Eisai price against GoodRx or RxSaver prices before choosing which to use at the pharmacy counter. The two discounts cannot be stacked.

For Mississippi patients who cannot afford even the $85 average cash price, Eisai's full patient assistance program (Dayvigo Access Program) provides free medication to uninsured or underinsured patients meeting income eligibility, generally at or below 400% of the federal poverty level (Eisai product information via FDA).

Is Compounded Lemborexant Legal in Mississippi?

Yes. A licensed 503A compounding pharmacy in Mississippi may legally prepare lemborexant for an individual patient when a prescriber has written a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare drug products not commercially available in the exact required form, or when a documented patient need justifies it (FDA 503A guidance).

The Mississippi State Board of Pharmacy (MSBP) licenses and inspects 503A compounders operating within the state. Out-of-state 503A pharmacies shipping into Mississippi must also hold a non-resident pharmacy permit from the MSBP. Compounded lemborexant is not subject to the same Schedule IV tracking requirements in every jurisdiction, but Mississippi law treats all controlled substance analogues consistently, the prescriber must still write a controlled substance prescription.

Clinically, compounded lemborexant suspensions or capsules at custom doses may benefit patients who cannot swallow the commercial 5 mg or 10 mg tablet, or who require an intermediate dose not commercially available. The FDA cautions that compounded drugs lack the same manufacturing quality controls as FDA-approved products and have not undergone the same safety and efficacy review (FDA compounding overview).

The HealthRX clinical team uses the following decision framework when evaluating compounded lemborexant for Mississippi patients. First, confirm 503A pharmacy licensure with the MSBP. Second, verify the pharmacy uses a validated analytical testing method (HPLC-UV or equivalent) for potency confirmation. Third, obtain a certificate of analysis for each batch. Fourth, start at the lowest effective dose (2.5 mg compounded, off-label) and titrate to 5 mg before considering 10 mg. Fifth, reassess at 4 weeks using the Insomnia Severity Index (ISI) to document objective response (ISI validation study).

Can You Get Dayvigo via Telehealth in Mississippi?

Telehealth prescribing of Dayvigo is legal in Mississippi. State law permits controlled substance prescribing via synchronous audio-video telehealth after the prescriber establishes a valid patient-prescriber relationship, which requires at minimum a real-time video examination. Audio-only prescribing of Schedule IV substances does not meet Mississippi's telemedicine standard for controlled substances (Mississippi State Medical Association guidance).

The federal Ryan Haight Act requires at least one in-person visit before prescribing controlled substances via telemedicine, though the DEA's 2023 temporary rule extension continues to allow fully telehealth-based prescribing of Schedule III and IV substances through registered providers during the ongoing post-pandemic regulatory period (DEA telemedicine rules). Patients should verify their specific telehealth provider's compliance with current DEA registration requirements before their first appointment.

Sleep medicine and psychiatry telehealth providers licensed in Mississippi can assess insomnia severity, screen for comorbid sleep apnea (which requires in-person polysomnography before DORA prescribing per AASM guidance), and send a Dayvigo prescription electronically to any Mississippi retail or mail-order pharmacy. The AASM explicitly recommends ruling out sleep-disordered breathing before initiating any hypnotic agent in patients with relevant risk factors (AASM position on hypnotics).

Insomnia affects an estimated 10% to 30% of adults chronically, with higher prevalence in women and older adults (NIH insomnia epidemiology). Mississippi's rural geography makes telehealth access to sleep specialists particularly important given that only a handful of board-certified sleep medicine physicians practice in the state's rural counties.

How Lemborexant Works: The Clinical Rationale

Lemborexant is a dual orexin receptor antagonist. It binds competitively and reversibly to both OX1R and OX2R, blocking the wake-promoting signal from orexin (hypocretin) peptides produced in the hypothalamus (mechanism review, PubMed). Unlike benzodiazepines and Z-drugs, lemborexant does not broadly suppress central nervous system activity. It selectively quiets the arousal drive without producing the global sedation associated with GABA-A receptor agonism.

This mechanism distinction matters clinically. SUNRISE-2 (N=900, published 2020 in Sleep Medicine) showed lemborexant 10 mg produced a statistically significant reduction in next-morning residual sleepiness measured by the Karolinska Sleepiness Scale compared to zolpidem ER 6.25 mg at the six-month endpoint (SUNRISE-2). That next-day profile is relevant for Mississippi patients who drive long distances for work, a common reality in a state with high rates of rural employment.

Lemborexant carries no evidence of physical dependence at approved doses in clinical trial data spanning up to 12 months, though it is still classified Schedule IV given the class precedent set by suvorexant and the potential for misuse (FDA prescribing information). The prescribing label recommends the lowest effective dose: 5 mg at bedtime, increasing to 10 mg only when the lower dose produces insufficient benefit.

Patients with severe hepatic impairment should not take lemborexant. Moderate hepatic impairment limits the maximum dose to 5 mg. Concurrent use of strong CYP3A inhibitors (such as ketoconazole or clarithromycin) can raise lemborexant plasma concentrations substantially and is contraindicated per the label (FDA label).

Comparing Dayvigo to Alternatives Available in Mississippi

Zolpidem immediate-release generic costs $4 to $10 per 30-day supply at most Mississippi pharmacies with a GoodRx coupon. Eszopiclone (Lunesta generic) runs $15 to $35 per month. Suvorexant (Belsomra) sits at approximately $280 to $310 per month cash price, similar to Dayvigo list, though a generic version may reach the market by late 2025 or 2026 (FDA ANDA tracker). Trazodone, used off-label for insomnia at 50 to 100 mg, costs under $10 per month generic.

The clinical differentiation of lemborexant over zolpidem centers on two points. Sleep architecture is better preserved: lemborexant does not suppress REM sleep at approved doses, whereas benzodiazepines and Z-drugs reduce REM duration in polysomnographic studies (sleep architecture review). Abuse potential is lower in DORA-class drugs: animal and human data show substantially less reinforcing behavior compared to triazolam at equipotent sedating doses (DORA abuse liability).

For Mississippi patients whose insomnia is primarily sleep-onset (trouble falling asleep), lemborexant 5 mg performs comparably to 10 mg in SUNRISE-1 trial data, which means a 5 mg prescription may stretch further if a patient splits costs. The FDA label does not prohibit 5 mg for sleep-onset insomnia; clinicians should document the specific insomnia phenotype to justify dose selection (FDA label).

Practical Steps for Mississippi Patients to Lower Their Dayvigo Cost

Start by asking the prescribing clinician to check your specific insurance formulary before writing the prescription. A 10-minute benefits inquiry at the pharmacy counter or via the insurer's drug lookup tool identifies whether Dayvigo is covered, what tier it is placed at, and whether prior authorization is required. This prevents a surprise $290 bill at pickup.

If your plan requires prior authorization, ask your provider to submit it the same day as the visit. The authorization process takes 3 to 15 business days in Mississippi. Submitting on day one avoids a gap between diagnosis and first fill. Request samples from the prescriber's office to bridge the authorization window; Eisai provides sample cards to licensed prescribers.

Cash-pay patients without insurance should compare prices at three to five pharmacies using GoodRx or RxSaver before choosing where to fill. A $15 to $20 difference per fill adds up to $180 to $240 per year. Mail-order pharmacies sometimes offer a 90-day supply at 2.5 times the 30-day cash price, effectively providing 2.5 months of medication for the cost of three individual fills.

Patients who fail all commercial options and cannot afford even the discounted cash price should apply directly to the Eisai Dayvigo Access Program. Income documentation (most recent federal tax return or pay stubs covering 60 days) is required. Eisai processes complete applications within 10 to 14 business days (FDA-registered manufacturer info).

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment recommended by the AASM, the American College of Physicians, and the National Institutes of Health consensus panel before any pharmacological agent is initiated (AASM CBT-I statement). CBT-I delivered via telehealth is available in Mississippi at costs ranging from $0 (through VA or Medicaid mental health benefits) to $120 per session privately. For patients with chronic insomnia disorder, completing a 6-to-8-session CBT-I course may reduce or eliminate the need for ongoing Dayvigo prescriptions entirely, lowering long-term costs.